Merck & Co., Inc. (MRK)
| Market Cap | 182.18B |
| Revenue (ttm) | 48.55B |
| Net Income (ttm) | 5.57B |
| Shares Out | 2.53B |
| EPS (ttm) | 2.20 |
| PE Ratio | 33.27 |
| Forward PE | 10.65 |
| Dividend | $2.52 (3.45%) |
| Ex-Dividend Date | Sep 14, 2021 |
| Volume | 10,968,784 |
| Open | 72.66 |
| Previous Close | 72.04 |
| Day's Range | 72.57 - 74.04 |
| 52-Week Range | 15.05 - 83.38 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 92.42 (+26.5%) |
| Est. Earnings Date | Oct 28, 2021 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as we...
Financial Performance
In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 92.42, which is an increase of 26.52% from the latest price.
News
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza pl...
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Should You Buy Merck Stock At $72?
The stock price of Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of arou...
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in c...
These 3 Dow Stocks Are Set to Soar in 2021's Second Half and Beyond
Scoop up these underestimated blue chips while they're not getting much love from the market.
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed at $71.93 in the latest trading session, marking a +0.35% move from the prior day.
Big Pharma Stocks Hit Hard by Drug Price Proposals
Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data
Merck & Co Inc (NYSE: MRK) announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative...
Could Pfizer and Merck Be Big Winners With COVID Pills?
The short answer: Yes.
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Tr...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemo as 1L Treatment for Patients With Metastatic TNBC Whose Tumors Expressed PD L1 (CPS ≥10)
Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Demonstrated Superior Recurrence-Free Survival in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Ve...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus Chemo ± Bev Reduced Risk of Death by 33% Vs Chemo ± Bev as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Pa...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination with Chemo for Certain Patients with Metastatic TNBC
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
What's Next For Merck Stock After A 5% Fall In A Week?
The stock price of Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, before a recent sell-off in pharmaceutica...
Option Trade: This Put Backspread In Merck Stock Offers Unlimited Upside Potential
For today's trade, we're looking at a put backspread in Merck. This trade profits if the stock stays flat or produces a big drop before expiration and the maximum upside potential is unlimited up to the...
Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial
Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (...
3 No-Brainer Warren Buffett Stocks to Buy Right Now
Not every name Berkshire Hathaway holds is right for all investors, but any of these three picks would be at home in almost any investor's portfolio.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
Merck (MRK) closed at $73.18 in the latest trading session, marking a -0.37% move from the prior day.
3 Dow Jones Stocks to Buy Hand Over Fist Right Now
These large companies still have what it takes to serve up big wins.
How Keytruda's Latest Approval in China Boosts Merck
Keytruda received its second regulatory approval in China for the treatment of esophageal cancer.
3 Smartest Big Pharma Stocks to Buy in September
You can go big this month with these three pharmaceutical stocks.